Literature DB >> 27470341

Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling.

M Ilamathi1, P C Prabu2, K Ashok Ayyappa3, V Sivaramakrishnan4.   

Abstract

Activation of the IL-6 mediated JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) oncogenic signalling plays a major role in hepatocellular carcinoma pathogenesis. The aim of this study is to assess the anti-tumour, anti-proliferative and apoptotic potential of artesunate and its capacity to modulate JAK-STAT pathway in a nitrosodiethylamine mediated experimental hepatocellular carcinoma model. Administration of nitrosodiethylamine (200mg/kg body weight by i.p. Injections) to rats resulted in alterations of liver pathophysiological parameters such as increased relative liver weight, and increased tumour nodule occurrence. It also increased the levels of serum marker enzymes (AST, ALT, ALP, LDH, and γGT) and tumour biomarker (AFP) levels suggestive of its capacity to cause liver tumourigenesis. Additionally, the immunohistochemistry of liver sections pertaining to nitrosodiethylamine administered animals showed increased detection of AgNOR, PCNA, and GST-Pi positive cells suggestive of its capacity to promote liver proliferation associated tumourigenesis. On the contrary, artesunate (25mg/kg bodyweight) supplementation to nitrosodiethylamine administered animals decreased all the above mentioned pathophysiological, biochemical, and immunohistochemistry parameters suggesting its anti-tumour and anti-proliferative potential. Furthermore, immunoblot analysis showed significant up-regulation of IL-6, GP130, JAK-2, STAT-3 (pY705), Bcl-xL, Bcl-2 and simultaneous down-regulation of Caspase-3, PARP and SOCS-3 in nitrosodiethylamine administered animals. Nevertheless, the immunoblot analysis revealed vice-versa on artesunate supplementation to nitrosodiethylamine administered animals, indicating promotion of the feedback loop inhibition mechanism through SOCS3 up-regulation thereby leading to suppression of JAK-STAT signalling. Overall all these findings substantiate that artesunate promotes anti-tumour, anti-proliferation and apoptosis against nitrosodiethylamine mediated hepatocellular carcinoma.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AgNOR; Anti-cancer agent; Artesunate; Hepatocellular carcinoma; Histopathology

Mesh:

Substances:

Year:  2016        PMID: 27470341     DOI: 10.1016/j.biopha.2016.04.061

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Poly(lactic-co-glycolic acid)-loaded nanoparticles of betulinic acid for improved treatment of hepatic cancer: characterization, in vitro and in vivo evaluations.

Authors:  Pranesh Kumar; Ashok K Singh; Vinit Raj; Amit Rai; Amit K Keshari; Dinesh Kumar; Biswanath Maity; Anand Prakash; Sabyasachi Maiti; Sudipta Saha
Journal:  Int J Nanomedicine       Date:  2018-02-16

2.  Novel Indole-fused benzo-oxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals.

Authors:  Ashok K Singh; Archana S Bhadauria; Umesh Kumar; Vinit Raj; Amit Rai; Pranesh Kumar; Amit K Keshari; Dinesh Kumar; Biswanath Maity; Sneha Nath; Anand Prakash; Sudipta Saha
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379

3.  Lipid nanobubbles as an ultrasound-triggered artesunate delivery system for imaging-guided, tumor-targeted chemotherapy.

Authors:  Shuang Gao; Xiaohui Cheng; Jinhua Li
Journal:  Onco Targets Ther       Date:  2019-03-06       Impact factor: 4.147

Review 4.  Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand.

Authors:  Karim Farmanpour-Kalalagh; Arman Beyraghdar Kashkooli; Alireza Babaei; Ali Rezaei; Alexander R van der Krol
Journal:  Front Plant Sci       Date:  2022-02-07       Impact factor: 5.753

Review 5.  Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review.

Authors:  Sareh Kamran; Ajantha Sinniah; Mahfoudh A M Abdulghani; Mohammed Abdullah Alshawsh
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 6.  Discovery and repurposing of artemisinin.

Authors:  Qiaoli Shi; Fei Xia; Qixin Wang; Fulong Liao; Qiuyan Guo; Chengchao Xu; Jigang Wang
Journal:  Front Med       Date:  2022-03-15       Impact factor: 9.927

7.  Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells.

Authors:  Li Chen; Chao Wang; Ning Hu; Hongmian Zhao
Journal:  RSC Adv       Date:  2019-01-09       Impact factor: 4.036

8.  Shuxie-1 Decoction Alleviated CUMS -Induced Liver Injury via IL-6/JAK2/STAT3 Signaling.

Authors:  Mengting Zhang; Wanhong Wu; Caoxin Huang; Teng Cai; Nengjiang Zhao; Suhuan Liu; Shuyu Yang
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.